Inovio Pharmaceuticals, Inc.
INO Real Time Price USDRecent trades of INO by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Sale $1,001 - $15,000 | Sep 08, 2020 |
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in INO holdings by institutional investors
Quarterly net insider trading by INO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jul 16, 2024 Issue: None
-
$50,000 Oct 20, 2023 Issue: Health Issues
-
$60,000 Jul 18, 2023 Issue: Health Issues
-
$130,000 Jan 20, 2023 Issue: Health Issues
-
$140,000 Oct 20, 2022 Issue: Health Issues
-
$140,000 Jul 20, 2022 Issue: Budget/Appropriations Health Issues
-
$150,000 Apr 20, 2022 Issue: Budget/Appropriations Health Issues
-
$60,000 Jan 20, 2022 Issue: Budget/Appropriations Health Issues Defense
-
$30,000 Jan 14, 2022 Issue: Health Issues
-
$60,000 Oct 20, 2021 Issue: Health Issues Defense Budget/Appropriations
-
$30,000 Oct 14, 2021 Issue: Health Issues
-
$60,000 Jul 20, 2021 Issue: Health Issues Defense Budget/Appropriations
-
$30,000 Jul 14, 2021 Issue: Health Issues
-
$60,000 Apr 26, 2021 Issue: Health Issues Budget/Appropriations Defense
-
$30,000 Apr 22, 2021 Issue: Health Issues
-
$30,000 Jan 11, 2021 Issue: Health Issues
-
$30,000 Oct 18, 2020 Issue: Health Issues
-
$30,000 Jul 07, 2020 Issue: Health Issues
-
$10,000 Jan 21, 2020 Issue: Pharmacy
-
$30,000 Oct 14, 2019 Issue: Pharmacy
-
$30,000 Jul 12, 2019 Issue: Pharmacy
-
$30,000 Apr 17, 2019 Issue: Pharmacy
-
$30,000 Jan 08, 2019 Issue: Pharmacy
-
$30,000 Oct 09, 2018 Issue: Pharmacy
-
$30,000 Jul 18, 2018 Issue: Pharmacy
-
$30,000 May 23, 2018 Issue: Pharmacy
-
$30,000 Jan 10, 2018 Issue: Pharmacy
-
$30,000 Oct 12, 2017 Issue: Pharmacy
-
$30,000 Jul 14, 2017 Issue: Pharmacy
-
$10,000 Apr 20, 2017 Issue: Pharmacy
Former government officials who have lobbied for INO
7 former government officials from 3 congressional offices at 3 lobbying firms have lobbied for INO, most recently Jan 20, 2023.
-
Susan Sweat Congress LC, LA & LD House Office (Wicker); LD Senate Member Office (Wicker)
-
Christopher Hodgson House Legislative Assistant (Scalise), Floor Assistant & Deputy Floor Director for House Majority Whip (Scalise), Deputy Director & Director of Legislative Affairs (Pence)
-
Cookab Hashemi House New Chief of Staff, Rep. Ruiz; Chief of Staff, Rep. Speier; Dep. Chief of Staff, Rep. Udall; Special Assistant, Sen. Bayh; Confidential Assistant, USDA; Assistant to Special Assistant to the President, White House Office of Political Affairs -
Anthony Lazarski Senate Senior Legislative Advisor, Senate Member Office (Inhofe); Professional Staff Member, Senate Armed Services Committee; Military Legislative Assistant, Senate Member Office (Inhofe)
-
Robert Wasinger Senate New Chief of Staff, Senator Sam Brownback -
Mona Mohib House New Director, Office of Intergovernmental Affairs, Dept. of Labor; Special Assistant, Office Intergovernmental Affairs, White House; Assoc. Director, Office Intergovernmental Affairs, White House
-
Amanda Anderson House New Legislative Intern for Rep. Dan Lipinski
INO Estimated quarterly lobbying spending
INO Revenue by Segment or Geography
New INO patent grants
-
Patent Title: Cancer vaccines targeting survivin and uses thereof Jul. 14, 2026
-
Patent Title: Vacuum-assisted electroporation devices, and related systems and methods Jun. 30, 2026
-
Patent Title: Hand-held electroporation device Jun. 02, 2026
-
Patent Title: Electroporation device with detachable needle array with lock-out system May. 12, 2026
-
Patent Title: Tolerable and minimally invasive skin electroporation device Dec. 09, 2025
-
Patent Title: Vaccines for recurrent respiratory papillomatosis and methods of using the same Nov. 25, 2025
-
Patent Title: Combination therapy to treat brain cancer Jul. 08, 2025
-
Patent Title: Cancer vaccines targeting muc16 and uses thereof Apr. 29, 2025
-
Patent Title: Minimally invasive dermal electroporation device Mar. 18, 2025
-
Patent Title: Cancer vaccines targeting boris and uses thereof Dec. 10, 2024
-
Patent Title: Oral mucosal electroporation device and use thereof Oct. 29, 2024
-
Patent Title: Cap for a hand-held electroporation device Sep. 10, 2024
-
Patent Title: Cancer vaccines targeting survivin and uses thereof Aug. 20, 2024
-
Patent Title: Intradermal jet injection electroporation Aug. 06, 2024
-
Patent Title: Cancer vaccines targeting mesothelin and uses thereof May. 21, 2024
-
Patent Title: Cap for a hand-held electroporation device Apr. 30, 2024
-
Patent Title: Electroporation device with detachable needle array with lock-out system Jan. 30, 2024
-
Patent Title: Cancer vaccines and methods of treatment using the same Oct. 31, 2023
-
Patent Title: Vaccines for recurrent respiratory papillomatosis and methods of using the same Sep. 05, 2023
-
Patent Title: Intradermal injection device Aug. 15, 2023
-
Patent Title: Method and device for minimally invasive in vivo transfection of adipose tissue using electroporation Jun. 27, 2023
-
Patent Title: Vaccines against coronavirus and methods of use May. 30, 2023
-
Patent Title: Hand-held electroporation device May. 23, 2023
-
Patent Title: Tolerable and minimally invasive skin electroporation device Jan. 31, 2023
-
Patent Title: Electroporation device and injection apparatus Oct. 18, 2022
-
Patent Title: Cancer vaccines targeting prame and uses thereof May. 24, 2022
-
Patent Title: Cancer vaccines targeting lemd1 and uses thereof May. 24, 2022
-
Patent Title: Device and method for single-needle in vivo electroporation May. 17, 2022
-
Patent Title: Minimally invasive dermal electroporation device Apr. 05, 2022
-
Patent Title: Electroporation device having a battery pack with power switch Apr. 05, 2022
-
Patent Title: Cancer vaccines targeting muc16 and uses thereof Feb. 01, 2022
-
Patent Title: Cancer vaccines targeting mesothelin and uses thereof Oct. 26, 2021
-
Patent Title: Cancer vaccines targeting boris and uses thereof Oct. 26, 2021
-
Patent Title: Multiple tissue layer electroporation applicator and device Aug. 24, 2021
-
Patent Title: Electroporation device with detachable needle array with lock-out system Jul. 27, 2021
-
Patent Title: Intradermal jet injection electroporation device Jun. 08, 2021
-
Patent Title: Cancer vaccines and methods of treatment using the same May. 18, 2021
-
Patent Title: Oral mucosal electroporation device and use thereof Feb. 02, 2021
-
Patent Title: Miniminally invasive dermal electroporation device Jun. 02, 2020
-
Patent Title: Vaccines for human papilloma virus and methods for using the same Mar. 19, 2019
-
Patent Title: Vaccines for human papilloma virus and methods for using the same Mar. 12, 2019
-
Patent Title: Wt1 vaccine Mar. 05, 2019
-
Patent Title: Oral mucosal electroporation device and use thereof Nov. 13, 2018
-
Patent Title: Dna antibody constructs and method of using same Oct. 02, 2018
-
Patent Title: Vaccines having an antigen and interleukin-23 as an adjuvant Jun. 06, 2017
-
Patent Title: Cross-protective arenavirus vaccines and their method of use Sep. 20, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to INO from public contracts
Recent insights relating to INO
Recent picks made for INO stock on CNBC
ETFs with the largest estimated holdings in INO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $INO stock a Buy, Sell, or Hold?
- What is the price target for $INO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $INO stock?
- Who owns the most shares of $INO stock?
- What funds own $INO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view INO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
- Address Plymouth Meeting, PA
- Market Cap 133.4 million
- Employees 112
- Industrial Classification Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc. (INO) Historical Stock Prices
Inovio Pharmaceuticals, Inc. (INO) closed at $1.29 on September 22, 2026. Over the past year its adjusted close ranged from $0.6560 to $2.65. Daily prices go back to January 2, 2014, 3,199 trading days in all.
- 1 month+9.32%
- 3 months+14.16%
- Year to date-25.86%
- 1 year-48.19%
- 3 years-72.70%
- 5 years-98.66%
- Max-99.06%
Quiver Premium charts INO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | 1.25 | 1.33 | 1.25 | 1.29 | 1.29 | 2,925,294 |
| Sep 21, 2026 | 1.24 | 1.28 | 1.22 | 1.24 | 1.24 | 2,723,325 |
| Sep 18, 2026 | 1.22 | 1.27 | 1.21 | 1.24 | 1.24 | 2,907,373 |
| Sep 17, 2026 | 1.15 | 1.25 | 1.15 | 1.21 | 1.21 | 2,724,202 |
| Sep 16, 2026 | 1.18 | 1.18 | 1.08 | 1.15 | 1.15 | 3,379,923 |
| Sep 15, 2026 | 1.20 | 1.20 | 1.14 | 1.16 | 1.16 | 2,647,925 |
| Sep 14, 2026 | 1.24 | 1.26 | 1.16 | 1.18 | 1.18 | 3,276,070 |
| Sep 11, 2026 | 1.30 | 1.31 | 1.23 | 1.25 | 1.25 | 2,392,904 |
| Sep 10, 2026 | 1.34 | 1.34 | 1.28 | 1.28 | 1.28 | 1,955,503 |
| Sep 9, 2026 | 1.41 | 1.45 | 1.32 | 1.32 | 1.32 | 2,687,338 |
| Sep 8, 2026 | 1.43 | 1.45 | 1.38 | 1.42 | 1.42 | 3,473,818 |
| Sep 4, 2026 | 1.35 | 1.43 | 1.35 | 1.43 | 1.43 | 2,910,140 |
| Sep 3, 2026 | 1.37 | 1.44 | 1.32 | 1.36 | 1.36 | 4,199,673 |
| Sep 2, 2026 | 1.34 | 1.42 | 1.29 | 1.36 | 1.36 | 4,425,304 |
| Sep 1, 2026 | 1.26 | 1.34 | 1.22 | 1.33 | 1.33 | 2,630,622 |
| Aug 31, 2026 | 1.30 | 1.37 | 1.26 | 1.27 | 1.27 | 5,628,024 |
| Aug 28, 2026 | 1.27 | 1.32 | 1.25 | 1.29 | 1.29 | 1,698,812 |
| Aug 27, 2026 | 1.29 | 1.31 | 1.25 | 1.26 | 1.26 | 2,308,148 |
| Aug 26, 2026 | 1.28 | 1.37 | 1.25 | 1.30 | 1.30 | 3,723,935 |
| Aug 25, 2026 | 1.25 | 1.30 | 1.24 | 1.29 | 1.29 | 3,604,907 |
| Aug 24, 2026 | 1.19 | 1.30 | 1.15 | 1.25 | 1.25 | 4,592,894 |
| Aug 21, 2026 | 1.23 | 1.24 | 1.15 | 1.18 | 1.18 | 5,015,594 |
| Aug 20, 2026 | 1.30 | 1.30 | 1.20 | 1.21 | 1.21 | 4,139,079 |
| Aug 19, 2026 | 1.22 | 1.32 | 1.15 | 1.30 | 1.30 | 6,970,649 |
| Aug 18, 2026 | 1.14 | 1.22 | 1.07 | 1.20 | 1.20 | 4,745,123 |
| Aug 17, 2026 | 1.07 | 1.15 | 1.04 | 1.15 | 1.15 | 6,487,413 |
| Aug 14, 2026 | 0.9295 | 1.10 | 0.8978 | 1.09 | 1.09 | 12,214,799 |
| Aug 13, 2026 | 0.8100 | 0.9624 | 0.7964 | 0.9001 | 0.9001 | 12,855,834 |
| Aug 12, 2026 | 0.7606 | 0.7800 | 0.7470 | 0.7700 | 0.7700 | 3,142,480 |
| Aug 11, 2026 | 0.7814 | 0.8100 | 0.7602 | 0.7658 | 0.7658 | 4,419,436 |
| Aug 10, 2026 | 0.6600 | 0.7524 | 0.6596 | 0.7364 | 0.7364 | 3,319,748 |
| Aug 7, 2026 | 0.6732 | 0.6845 | 0.6410 | 0.6680 | 0.6680 | 3,051,079 |
| Aug 6, 2026 | 0.6738 | 0.6849 | 0.6600 | 0.6738 | 0.6738 | 1,731,539 |
| Aug 5, 2026 | 0.6711 | 0.6899 | 0.6610 | 0.6770 | 0.6770 | 2,289,258 |
| Aug 4, 2026 | 0.7064 | 0.7198 | 0.6451 | 0.6631 | 0.6631 | 3,991,944 |
| Aug 3, 2026 | 0.6900 | 0.7238 | 0.6800 | 0.6968 | 0.6968 | 7,630,984 |
| Jul 31, 2026 | 0.6500 | 0.6801 | 0.6206 | 0.6770 | 0.6770 | 12,700,118 |
| Jul 30, 2026 | 0.7300 | 0.7300 | 0.5632 | 0.6560 | 0.6560 | 33,394,735 |
| Jul 29, 2026 | 1.03 | 1.08 | 1.01 | 1.04 | 1.04 | 1,814,995 |
| Jul 28, 2026 | 0.9800 | 1.03 | 0.9502 | 1.03 | 1.03 | 1,031,448 |
| Jul 27, 2026 | 0.9821 | 1.00 | 0.9611 | 0.9651 | 0.9651 | 1,874,732 |
| Jul 24, 2026 | 1.03 | 1.04 | 0.9601 | 0.9701 | 0.9701 | 3,719,690 |
| Jul 23, 2026 | 1.06 | 1.06 | 1.00 | 1.02 | 1.02 | 2,270,990 |
| Jul 22, 2026 | 1.11 | 1.11 | 1.06 | 1.06 | 1.06 | 969,856 |
| Jul 21, 2026 | 1.09 | 1.10 | 1.07 | 1.10 | 1.10 | 594,249 |
| Jul 20, 2026 | 1.11 | 1.12 | 1.06 | 1.09 | 1.09 | 2,043,105 |
| Jul 17, 2026 | 1.13 | 1.15 | 1.10 | 1.12 | 1.12 | 829,487 |
| Jul 16, 2026 | 1.17 | 1.18 | 1.12 | 1.12 | 1.12 | 1,076,153 |
| Jul 15, 2026 | 1.17 | 1.18 | 1.15 | 1.17 | 1.17 | 616,377 |
| Jul 14, 2026 | 1.17 | 1.21 | 1.15 | 1.16 | 1.16 | 975,258 |
| Jul 13, 2026 | 1.15 | 1.21 | 1.14 | 1.16 | 1.16 | 1,122,966 |
| Jul 10, 2026 | 1.19 | 1.20 | 1.13 | 1.18 | 1.18 | 1,588,566 |
| Jul 9, 2026 | 1.23 | 1.25 | 1.18 | 1.19 | 1.19 | 1,184,905 |
| Jul 8, 2026 | 1.20 | 1.24 | 1.17 | 1.21 | 1.21 | 1,564,568 |
| Jul 7, 2026 | 1.17 | 1.22 | 1.13 | 1.21 | 1.21 | 1,555,052 |
| Jul 6, 2026 | 1.21 | 1.23 | 1.15 | 1.16 | 1.16 | 1,357,878 |
| Jul 2, 2026 | 1.20 | 1.27 | 1.18 | 1.22 | 1.22 | 2,771,150 |
| Jul 1, 2026 | 1.12 | 1.19 | 1.11 | 1.19 | 1.19 | 3,206,448 |
| Jun 30, 2026 | 1.12 | 1.12 | 1.09 | 1.10 | 1.10 | 1,041,698 |
| Jun 29, 2026 | 1.10 | 1.13 | 1.09 | 1.12 | 1.12 | 1,707,890 |
| Jun 26, 2026 | 1.08 | 1.11 | 1.07 | 1.10 | 1.10 | 1,194,902 |
| Jun 25, 2026 | 1.11 | 1.12 | 1.08 | 1.08 | 1.08 | 1,497,774 |
| Jun 24, 2026 | 1.12 | 1.16 | 1.10 | 1.10 | 1.10 | 1,565,433 |
| Jun 23, 2026 | 1.09 | 1.16 | 1.09 | 1.13 | 1.13 | 1,178,672 |
| Jun 22, 2026 | 1.11 | 1.14 | 1.10 | 1.11 | 1.11 | 1,090,750 |
| Jun 18, 2026 | 1.11 | 1.16 | 1.07 | 1.11 | 1.11 | 2,757,454 |
| Jun 17, 2026 | 1.13 | 1.15 | 1.10 | 1.11 | 1.11 | 1,109,160 |
| Jun 16, 2026 | 1.11 | 1.14 | 1.08 | 1.11 | 1.11 | 1,357,584 |
| Jun 15, 2026 | 1.12 | 1.15 | 1.10 | 1.10 | 1.10 | 911,869 |
| Jun 12, 2026 | 1.10 | 1.15 | 1.10 | 1.10 | 1.10 | 1,113,083 |
| Jun 11, 2026 | 1.09 | 1.11 | 1.06 | 1.10 | 1.10 | 1,419,017 |
| Jun 10, 2026 | 1.07 | 1.13 | 1.07 | 1.09 | 1.09 | 881,398 |
| Jun 9, 2026 | 1.11 | 1.13 | 1.08 | 1.10 | 1.10 | 1,158,456 |
| Jun 8, 2026 | 1.09 | 1.11 | 1.07 | 1.09 | 1.09 | 1,436,517 |
| Jun 5, 2026 | 1.17 | 1.17 | 1.06 | 1.07 | 1.07 | 3,318,737 |
| Jun 4, 2026 | 1.15 | 1.20 | 1.15 | 1.16 | 1.16 | 1,307,856 |
| Jun 3, 2026 | 1.21 | 1.22 | 1.13 | 1.14 | 1.14 | 1,769,289 |
| Jun 2, 2026 | 1.27 | 1.28 | 1.21 | 1.21 | 1.21 | 1,531,356 |
| Jun 1, 2026 | 1.30 | 1.30 | 1.26 | 1.28 | 1.28 | 1,749,470 |
| May 29, 2026 | 1.30 | 1.36 | 1.29 | 1.31 | 1.31 | 1,151,950 |
| May 28, 2026 | 1.26 | 1.33 | 1.24 | 1.30 | 1.30 | 1,388,085 |
| May 27, 2026 | 1.26 | 1.30 | 1.23 | 1.25 | 1.25 | 1,422,114 |
| May 26, 2026 | 1.35 | 1.37 | 1.26 | 1.26 | 1.26 | 2,142,631 |
| May 22, 2026 | 1.31 | 1.45 | 1.31 | 1.35 | 1.35 | 3,320,302 |
| May 21, 2026 | 1.25 | 1.34 | 1.22 | 1.33 | 1.33 | 3,451,302 |
| May 20, 2026 | 1.23 | 1.30 | 1.20 | 1.23 | 1.23 | 2,429,300 |
| May 19, 2026 | 1.26 | 1.34 | 1.20 | 1.22 | 1.22 | 4,860,678 |
| May 18, 2026 | 1.34 | 1.45 | 1.21 | 1.22 | 1.22 | 5,334,644 |
| May 15, 2026 | 1.35 | 1.41 | 1.30 | 1.30 | 1.30 | 1,950,912 |
| May 14, 2026 | 1.29 | 1.40 | 1.25 | 1.36 | 1.36 | 2,512,640 |
| May 13, 2026 | 1.45 | 1.45 | 1.30 | 1.34 | 1.34 | 3,505,015 |
| May 12, 2026 | 1.40 | 1.47 | 1.35 | 1.41 | 1.41 | 2,997,172 |
| May 11, 2026 | 1.63 | 1.64 | 1.39 | 1.43 | 1.43 | 8,046,154 |
| May 8, 2026 | 1.41 | 1.79 | 1.36 | 1.46 | 1.46 | 21,007,953 |
| May 7, 2026 | 1.31 | 1.43 | 1.26 | 1.37 | 1.37 | 9,148,733 |
| May 6, 2026 | 1.15 | 1.28 | 1.13 | 1.24 | 1.24 | 3,064,905 |
| May 5, 2026 | 1.15 | 1.20 | 1.14 | 1.14 | 1.14 | 1,519,556 |
| May 4, 2026 | 1.11 | 1.15 | 1.10 | 1.14 | 1.14 | 1,389,699 |
| May 1, 2026 | 1.13 | 1.14 | 1.10 | 1.10 | 1.10 | 1,106,678 |
| Apr 30, 2026 | 1.13 | 1.15 | 1.11 | 1.12 | 1.12 | 532,033 |
| Apr 29, 2026 | 1.16 | 1.16 | 1.12 | 1.12 | 1.12 | 1,038,563 |
| Apr 28, 2026 | 1.17 | 1.18 | 1.15 | 1.15 | 1.15 | 1,080,406 |
| Apr 27, 2026 | 1.15 | 1.23 | 1.14 | 1.17 | 1.17 | 2,882,357 |
| Apr 24, 2026 | 1.15 | 1.16 | 1.11 | 1.15 | 1.15 | 721,524 |
| Apr 23, 2026 | 1.16 | 1.16 | 1.13 | 1.14 | 1.14 | 691,374 |
| Apr 22, 2026 | 1.14 | 1.15 | 1.12 | 1.14 | 1.14 | 698,745 |
| Apr 21, 2026 | 1.19 | 1.20 | 1.12 | 1.13 | 1.13 | 2,092,160 |
| Apr 20, 2026 | 1.20 | 1.21 | 1.17 | 1.18 | 1.18 | 1,972,449 |
| Apr 17, 2026 | 1.16 | 1.20 | 1.16 | 1.19 | 1.19 | 2,034,120 |
| Apr 16, 2026 | 1.20 | 1.23 | 1.14 | 1.16 | 1.16 | 2,285,985 |
| Apr 15, 2026 | 1.12 | 1.20 | 1.08 | 1.19 | 1.19 | 7,276,027 |
| Apr 14, 2026 | 1.11 | 1.13 | 1.09 | 1.11 | 1.11 | 2,019,888 |
| Apr 13, 2026 | 1.06 | 1.11 | 1.05 | 1.09 | 1.09 | 2,300,273 |
| Apr 10, 2026 | 1.06 | 1.07 | 1.03 | 1.06 | 1.06 | 2,510,016 |
| Apr 9, 2026 | 1.09 | 1.11 | 1.05 | 1.05 | 1.05 | 2,919,304 |
| Apr 8, 2026 | 1.09 | 1.13 | 1.07 | 1.09 | 1.09 | 2,993,816 |
| Apr 7, 2026 | 1.12 | 1.13 | 1.05 | 1.05 | 1.05 | 3,955,990 |
| Apr 6, 2026 | 1.15 | 1.15 | 1.11 | 1.13 | 1.13 | 3,035,548 |
| Apr 2, 2026 | 1.35 | 1.36 | 1.06 | 1.13 | 1.13 | 19,933,832 |
| Apr 1, 2026 | 1.76 | 1.78 | 1.72 | 1.74 | 1.74 | 531,087 |
| Mar 31, 2026 | 1.68 | 1.78 | 1.67 | 1.74 | 1.74 | 802,613 |
| Mar 30, 2026 | 1.61 | 1.69 | 1.56 | 1.67 | 1.67 | 1,152,733 |
| Mar 27, 2026 | 1.54 | 1.62 | 1.50 | 1.61 | 1.61 | 1,491,437 |
| Mar 26, 2026 | 1.54 | 1.58 | 1.53 | 1.55 | 1.55 | 381,784 |
| Mar 25, 2026 | 1.58 | 1.61 | 1.53 | 1.54 | 1.54 | 572,963 |
| Mar 24, 2026 | 1.62 | 1.65 | 1.57 | 1.57 | 1.57 | 691,172 |
| Mar 23, 2026 | 1.59 | 1.62 | 1.53 | 1.61 | 1.61 | 978,389 |
| Mar 20, 2026 | 1.66 | 1.67 | 1.58 | 1.58 | 1.58 | 993,944 |
| Mar 19, 2026 | 1.64 | 1.68 | 1.60 | 1.65 | 1.65 | 808,170 |
| Mar 18, 2026 | 1.66 | 1.67 | 1.62 | 1.66 | 1.66 | 574,780 |
| Mar 17, 2026 | 1.65 | 1.72 | 1.63 | 1.68 | 1.68 | 619,952 |
| Mar 16, 2026 | 1.67 | 1.70 | 1.59 | 1.63 | 1.63 | 831,426 |
| Mar 13, 2026 | 1.72 | 1.77 | 1.65 | 1.66 | 1.66 | 924,613 |
| Mar 12, 2026 | 1.68 | 1.71 | 1.65 | 1.68 | 1.68 | 758,434 |
| Mar 11, 2026 | 1.74 | 1.78 | 1.69 | 1.69 | 1.69 | 1,095,602 |
| Mar 10, 2026 | 1.72 | 1.77 | 1.72 | 1.73 | 1.73 | 561,334 |
| Mar 9, 2026 | 1.74 | 1.77 | 1.72 | 1.73 | 1.73 | 772,390 |
| Mar 6, 2026 | 1.69 | 1.77 | 1.68 | 1.74 | 1.74 | 583,063 |
| Mar 5, 2026 | 1.75 | 1.75 | 1.65 | 1.68 | 1.68 | 760,069 |
| Mar 4, 2026 | 1.71 | 1.80 | 1.71 | 1.73 | 1.73 | 684,004 |
| Mar 3, 2026 | 1.73 | 1.74 | 1.68 | 1.68 | 1.68 | 579,750 |
| Mar 2, 2026 | 1.76 | 1.77 | 1.69 | 1.74 | 1.74 | 597,450 |
| Feb 27, 2026 | 1.79 | 1.82 | 1.76 | 1.81 | 1.81 | 352,967 |
| Feb 26, 2026 | 1.83 | 1.83 | 1.76 | 1.79 | 1.79 | 449,184 |
| Feb 25, 2026 | 1.90 | 1.94 | 1.85 | 1.85 | 1.85 | 866,964 |
| Feb 24, 2026 | 1.81 | 2.03 | 1.81 | 1.89 | 1.89 | 2,231,629 |
| Feb 23, 2026 | 1.68 | 1.84 | 1.68 | 1.81 | 1.81 | 1,298,342 |
| Feb 20, 2026 | 1.68 | 1.74 | 1.64 | 1.73 | 1.73 | 965,124 |
| Feb 19, 2026 | 1.63 | 1.74 | 1.63 | 1.72 | 1.72 | 846,161 |
| Feb 18, 2026 | 1.63 | 1.68 | 1.63 | 1.67 | 1.67 | 420,748 |
| Feb 17, 2026 | 1.58 | 1.67 | 1.56 | 1.63 | 1.63 | 734,288 |
| Feb 13, 2026 | 1.58 | 1.62 | 1.57 | 1.61 | 1.61 | 369,457 |
| Feb 12, 2026 | 1.62 | 1.64 | 1.55 | 1.58 | 1.58 | 702,478 |
| Feb 11, 2026 | 1.69 | 1.71 | 1.56 | 1.61 | 1.61 | 1,383,785 |
| Feb 10, 2026 | 1.68 | 1.77 | 1.66 | 1.69 | 1.69 | 1,398,863 |
| Feb 9, 2026 | 1.65 | 1.71 | 1.60 | 1.69 | 1.69 | 1,116,234 |
| Feb 6, 2026 | 1.60 | 1.73 | 1.58 | 1.66 | 1.66 | 1,235,535 |
| Feb 5, 2026 | 1.68 | 1.73 | 1.53 | 1.56 | 1.56 | 1,186,516 |
| Feb 4, 2026 | 1.68 | 1.73 | 1.64 | 1.67 | 1.67 | 1,137,325 |
| Feb 3, 2026 | 1.70 | 1.78 | 1.66 | 1.69 | 1.69 | 1,225,023 |
| Feb 2, 2026 | 1.62 | 1.74 | 1.57 | 1.70 | 1.70 | 1,614,341 |
| Jan 30, 2026 | 1.60 | 1.67 | 1.56 | 1.63 | 1.63 | 992,501 |
| Jan 29, 2026 | 1.52 | 1.64 | 1.50 | 1.61 | 1.61 | 1,922,086 |
| Jan 28, 2026 | 1.52 | 1.54 | 1.49 | 1.53 | 1.53 | 644,228 |
| Jan 27, 2026 | 1.51 | 1.53 | 1.49 | 1.53 | 1.53 | 523,457 |
| Jan 26, 2026 | 1.51 | 1.51 | 1.48 | 1.51 | 1.51 | 1,319,862 |
| Jan 23, 2026 | 1.54 | 1.56 | 1.48 | 1.51 | 1.51 | 860,683 |
| Jan 22, 2026 | 1.52 | 1.56 | 1.51 | 1.56 | 1.56 | 638,784 |
| Jan 21, 2026 | 1.52 | 1.54 | 1.49 | 1.51 | 1.51 | 750,563 |
| Jan 20, 2026 | 1.51 | 1.55 | 1.47 | 1.51 | 1.51 | 946,993 |
| Jan 16, 2026 | 1.57 | 1.58 | 1.52 | 1.52 | 1.52 | 1,381,720 |
| Jan 15, 2026 | 1.66 | 1.66 | 1.58 | 1.58 | 1.58 | 870,542 |
| Jan 14, 2026 | 1.60 | 1.70 | 1.60 | 1.64 | 1.64 | 1,199,209 |
| Jan 13, 2026 | 1.53 | 1.62 | 1.50 | 1.60 | 1.60 | 1,725,197 |
| Jan 12, 2026 | 1.58 | 1.58 | 1.51 | 1.54 | 1.54 | 1,785,278 |
| Jan 9, 2026 | 1.62 | 1.67 | 1.54 | 1.56 | 1.56 | 1,714,493 |
| Jan 8, 2026 | 1.67 | 1.67 | 1.59 | 1.61 | 1.61 | 1,023,107 |
| Jan 7, 2026 | 1.62 | 1.72 | 1.59 | 1.67 | 1.67 | 1,894,170 |
| Jan 6, 2026 | 1.57 | 1.61 | 1.49 | 1.60 | 1.60 | 4,541,853 |
| Jan 5, 2026 | 1.71 | 1.72 | 1.59 | 1.59 | 1.59 | 3,478,860 |
| Jan 2, 2026 | 1.75 | 1.79 | 1.66 | 1.69 | 1.69 | 1,885,422 |
| Dec 31, 2025 | 1.77 | 1.85 | 1.73 | 1.74 | 1.74 | 1,354,387 |
| Dec 30, 2025 | 1.72 | 1.77 | 1.68 | 1.76 | 1.76 | 2,370,669 |
| Dec 29, 2025 | 1.90 | 1.94 | 1.72 | 1.73 | 1.73 | 6,144,354 |
| Dec 26, 2025 | 2.27 | 2.31 | 2.21 | 2.29 | 2.29 | 544,382 |
| Dec 24, 2025 | 2.16 | 2.37 | 2.16 | 2.25 | 2.25 | 712,233 |
| Dec 23, 2025 | 2.26 | 2.26 | 2.11 | 2.15 | 2.15 | 2,199,566 |
| Dec 22, 2025 | 2.31 | 2.36 | 2.23 | 2.25 | 2.25 | 1,534,563 |
| Dec 19, 2025 | 2.38 | 2.42 | 2.26 | 2.28 | 2.28 | 2,231,962 |
| Dec 18, 2025 | 2.59 | 2.63 | 2.29 | 2.37 | 2.37 | 2,196,012 |
| Dec 17, 2025 | 2.31 | 2.72 | 2.30 | 2.60 | 2.60 | 4,554,802 |
| Dec 16, 2025 | 2.28 | 2.34 | 2.19 | 2.32 | 2.32 | 1,309,979 |
| Dec 15, 2025 | 2.07 | 2.37 | 2.03 | 2.26 | 2.26 | 2,789,750 |
| Dec 12, 2025 | 2.13 | 2.17 | 2.04 | 2.06 | 2.06 | 745,581 |
| Dec 11, 2025 | 2.17 | 2.21 | 2.13 | 2.13 | 2.13 | 903,503 |
| Dec 10, 2025 | 2.18 | 2.27 | 2.13 | 2.17 | 2.17 | 1,227,310 |
| Dec 9, 2025 | 2.24 | 2.24 | 2.07 | 2.18 | 2.18 | 1,683,310 |
| Dec 8, 2025 | 2.08 | 2.17 | 2.06 | 2.09 | 2.09 | 1,199,244 |
| Dec 5, 2025 | 2.02 | 2.08 | 1.99 | 2.07 | 2.07 | 1,000,093 |
| Dec 4, 2025 | 2.01 | 2.06 | 1.96 | 2.02 | 2.02 | 679,825 |
| Dec 3, 2025 | 1.91 | 2.04 | 1.90 | 2.02 | 2.02 | 802,027 |
| Dec 2, 2025 | 1.93 | 1.93 | 1.86 | 1.92 | 1.92 | 1,447,696 |
| Dec 1, 2025 | 2.06 | 2.10 | 1.91 | 1.92 | 1.92 | 1,061,385 |
| Nov 28, 2025 | 2.00 | 2.07 | 1.97 | 2.06 | 2.06 | 594,500 |
| Nov 26, 2025 | 1.82 | 1.99 | 1.81 | 1.96 | 1.96 | 1,332,683 |
| Nov 25, 2025 | 1.82 | 1.83 | 1.76 | 1.81 | 1.81 | 623,558 |
| Nov 24, 2025 | 1.79 | 1.85 | 1.78 | 1.81 | 1.81 | 932,565 |
| Nov 21, 2025 | 1.73 | 1.79 | 1.72 | 1.76 | 1.76 | 755,111 |
| Nov 20, 2025 | 1.85 | 1.88 | 1.72 | 1.73 | 1.73 | 831,280 |
| Nov 19, 2025 | 1.90 | 1.91 | 1.76 | 1.78 | 1.78 | 1,573,706 |
| Nov 18, 2025 | 1.98 | 1.99 | 1.89 | 1.89 | 1.89 | 1,217,074 |
| Nov 17, 2025 | 2.08 | 2.11 | 1.96 | 1.98 | 1.98 | 1,233,876 |
| Nov 14, 2025 | 1.98 | 2.10 | 1.95 | 2.05 | 2.05 | 1,487,610 |
| Nov 13, 2025 | 1.97 | 2.02 | 1.93 | 1.95 | 1.95 | 951,465 |
| Nov 12, 2025 | 2.02 | 2.07 | 1.95 | 1.96 | 1.96 | 942,330 |
| Nov 11, 2025 | 2.00 | 2.04 | 1.90 | 2.00 | 2.00 | 3,408,677 |
| Nov 10, 2025 | 2.17 | 2.23 | 2.12 | 2.15 | 2.15 | 1,269,020 |
| Nov 7, 2025 | 2.20 | 2.22 | 2.02 | 2.12 | 2.12 | 1,761,898 |
| Nov 6, 2025 | 2.28 | 2.32 | 2.21 | 2.25 | 2.25 | 941,721 |
| Nov 5, 2025 | 2.42 | 2.44 | 2.27 | 2.29 | 2.29 | 1,912,638 |
| Nov 4, 2025 | 2.43 | 2.58 | 2.41 | 2.43 | 2.43 | 2,074,914 |
| Nov 3, 2025 | 2.35 | 2.50 | 2.29 | 2.50 | 2.50 | 2,273,616 |
| Oct 31, 2025 | 2.40 | 2.42 | 2.31 | 2.35 | 2.35 | 542,701 |
| Oct 30, 2025 | 2.45 | 2.46 | 2.36 | 2.36 | 2.36 | 801,497 |
| Oct 29, 2025 | 2.59 | 2.67 | 2.42 | 2.43 | 2.43 | 1,204,761 |
| Oct 28, 2025 | 2.50 | 2.67 | 2.44 | 2.58 | 2.58 | 1,598,972 |
| Oct 27, 2025 | 2.56 | 2.66 | 2.47 | 2.49 | 2.49 | 2,168,213 |
| Oct 24, 2025 | 2.28 | 2.34 | 2.27 | 2.33 | 2.33 | 628,118 |
| Oct 23, 2025 | 2.23 | 2.31 | 2.21 | 2.25 | 2.25 | 495,846 |
| Oct 22, 2025 | 2.30 | 2.31 | 2.22 | 2.22 | 2.22 | 1,250,183 |
| Oct 21, 2025 | 2.47 | 2.49 | 2.31 | 2.33 | 2.33 | 1,631,833 |
| Oct 20, 2025 | 2.40 | 2.48 | 2.38 | 2.47 | 2.47 | 519,257 |
| Oct 17, 2025 | 2.42 | 2.44 | 2.35 | 2.35 | 2.35 | 709,589 |
| Oct 16, 2025 | 2.58 | 2.63 | 2.41 | 2.46 | 2.46 | 842,634 |
| Oct 15, 2025 | 2.49 | 2.58 | 2.45 | 2.54 | 2.54 | 731,530 |
| Oct 14, 2025 | 2.41 | 2.46 | 2.37 | 2.44 | 2.44 | 782,995 |
| Oct 13, 2025 | 2.59 | 2.63 | 2.40 | 2.47 | 2.47 | 886,031 |
| Oct 10, 2025 | 2.62 | 2.66 | 2.53 | 2.57 | 2.57 | 1,065,169 |
| Oct 9, 2025 | 2.60 | 2.65 | 2.52 | 2.65 | 2.65 | 919,121 |
| Oct 8, 2025 | 2.38 | 2.68 | 2.36 | 2.56 | 2.56 | 2,398,926 |
| Oct 7, 2025 | 2.41 | 2.44 | 2.28 | 2.39 | 2.39 | 1,014,412 |
| Oct 6, 2025 | 2.43 | 2.58 | 2.41 | 2.41 | 2.41 | 977,645 |
| Oct 3, 2025 | 2.48 | 2.54 | 2.38 | 2.43 | 2.43 | 778,466 |
| Oct 2, 2025 | 2.40 | 2.50 | 2.40 | 2.46 | 2.46 | 672,257 |
| Oct 1, 2025 | 2.34 | 2.50 | 2.34 | 2.37 | 2.37 | 869,916 |
| Sep 30, 2025 | 2.44 | 2.44 | 2.27 | 2.34 | 2.34 | 896,965 |
| Sep 29, 2025 | 2.50 | 2.54 | 2.41 | 2.44 | 2.44 | 638,431 |
| Sep 26, 2025 | 2.44 | 2.48 | 2.38 | 2.48 | 2.48 | 617,324 |
| Sep 25, 2025 | 2.48 | 2.50 | 2.39 | 2.43 | 2.43 | 562,247 |
| Sep 24, 2025 | 2.43 | 2.52 | 2.39 | 2.52 | 2.52 | 879,812 |
| Sep 23, 2025 | 2.49 | 2.51 | 2.37 | 2.41 | 2.41 | 855,499 |
| Sep 22, 2025 | 2.32 | 2.50 | 2.28 | 2.49 | 2.49 | 846,221 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at INO, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|